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Inhibition of the mammalian target of rapamycin
complex 1 signaling pathway reduces itch
behaviour in mice
Ilona Obaraa,b,*, Maria C. Medranoc, Je´re´my Signoret-Genestb, Lydia Jime´nez-Dı´azd, Sandrine M. Ge´rantona,
Stephen P. Hunta
Abstract
Activated mammalian target of rapamycin (P-mTOR) has been shown to maintain the sensitivity of subsets of small-diameter primary
afferent A-nociceptors. Local or systemic inhibition of the mTOR complex 1 (mTORC1) pathway reduced punctate mechanical and cold
sensitivity in neuropathic pain and therefore offered a new approach to chronic pain control. In this study, we have investigated the effects
of the rapamycin analog temsirolimus (CCI-779) on itch. Bouts of scratching inducedby the histamine-dependent pruritogenic compound
48/80 and histamine-independent pruritogens, chloroquine and SLIGRL-NH2, injected intradermally were significantly reduced by local
(intradermal) or systemic (intraperitoneal, i.p.) pretreatment with CCI-779. We also investigated the action of metformin, a drug taken to
control type2diabetes and recently shown to inhibitmTORC1 in vivo. Although the response tononhistaminergic stimuliwas reducedat all
of the time points tested, scratching to compound 48/80wasmodified bymetformin only when the drugwas injected 24 hours before this
pruritogen. We also examined the colocalization of P-mTOR with gastrin-releasing peptide, a putative marker for some itch-sensitive
primary afferents, and found that P-mTORwas coexpressed in less than 5%of gastrin-releasing peptide–positive fibers in themouse skin.
Taken together, the data highlight the role that P-mTOR-positive A-fibers play in itch signaling and underline the importance of the
mTORC1 pathway in the regulation of homeostatic primary afferent functions such as pain and itch. The actions of the antidiabetic drug
metformin in ameliorating nonhistamine-mediated itch also suggest a new therapeutic route for the control of this category of pruritus.
Keywords:Mammalian target of rapamycin complex 1, Gastrin-releasing peptide, Temsirolimus (CCI-779), Metformin, Itch, Mice
1. Introduction
Small-diameter primary afferent fibers have been classified in
a number of ways principally according to their receptive field
properties, complement of receptor proteins, and neurotrans-
mitter or protein kinase content.10,15,30,44 In some cases, it has
been possible to demonstrate that particular molecular signa-
tures correspond to functional subtypes of primary afferent. For
example, nociceptors that respond to chloroquine and signal itch,
but not pain, can be identified by the expression of specific
members of the Mas family of G-protein-coupled receptors
(MrgprA3).12 Also, gastrin-releasing peptide (GRP)–expressing
primary afferents have also been proposed to play a role in itch
sensation.42,45
Our previous work identified 1 group of small-diameter Ad-
nociceptors as containing an activated form of the mammalian
target of rapamycin (mTOR), a kinase that maintains the
excitability of these A-fibers.9,18,31 mTOR belongs to the
phosphatidylinositol 3-kinase–related kinase protein family and
forms at least 2 multiprotein complexes known as mTOR
complex 1 (mTORC1) and mTOR complex 2 (mTORC2).24
Although mTORC1 is well understood and recognised as an
evolutionarily conserved environmental sensor signaling changes
to diverse cues and displays acute sensitivity to rapamycin,47
much less is known about mTORC2. In a phosphorylated form,
mTORC1 (P-mTORC1) can activate downstream pathways
involving ribosomal protein S6K (S6 kinase) and 4EBP (eIF4E;
eukaryotic initiation factor 4E–binding protein) and has been
shown to promote protein synthesis in cell bodies, axons, and
dendrites.7,19,32,47 This kinase also can be negatively regulated
by the adenosine monophosphate–activated protein kinase
(AMPK) through the activation of mTORC1’s negative regulator
tuberous sclerosis complex 2.6,8 This results in a profound
inhibition of mTORC1 and its downstream targets involved in
translational control (eg, 4EBP and S6 kinase).6,8 Our previous
investigations revealed that a subset of P-mTORC1 containing
A-nociceptive primary afferents supported the increased punc-
tate mechanical sensitivity that develops around a site of injury
(also referred to as secondary hyperalgesia) but did not influence
peripheral sensitization or acute pain responses.9,18,31 For
example, it was shown that blocking the actions of mTORC1
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peripherally and/or systemically with inhibitors such as rapamy-
cin, the rapamycin ester temsirolimus (CCI-779), or an ATP-
competitive inhibitor Torin-1 reduced both the spread of
punctate mechanical sensitivity after inflammation or local
injury and mechanical hypersensitivity in animal models of
neuropathic pain. Importantly, mTORC1 inhibitors did not
modulate the C-fiber-evoked peripheral or central sensitiza-
tion induced by capsaicin injection, confirming A-fibers as the
principle target for locally and/or systemically applied
mTORC1 inhibitors.30,31,33
Here, we have extended the list of functionsmediated bymTOR-
positive primary afferents and investigated the involvement of
mTORC1 in itch signaling. Although recent research has empha-
sized the role of C-fibers in pruritus research, there is evidence that
some A-fibers are also sensitive to the 2 classes of histaminergic
and nonhistaminergic stimuli widely used to induce itch.4,11,27,28,34
Thus, we investigated the antipruritic action of CCI-779 and
metformin, a drug widely given to treat type 2 diabetes and recently
shown to inhibit mTORC1 signaling through AMPK pathway found
in many cell types including neurons.6,8,26
2. Materials and methods
2.1. C57BL/6J mice
Adult male C57BL/6J (B6) mice (8 weeks of age; 25-30 g;
Harlan OLAC, Bicester, United Kingdom) were allowed to
acclimate to the colony room (Central Biological Services;
University College London, United Kingdom) for at least 7
days after arrival and were housed in polyethylene cages
(4 per cage), controlled for temperature (21˚C) and humidity
(55%) under a regular 12-hour day/night cycle (lights on at 8:
00 AM and lights off at 8:00 PM). Standard laboratory rodent
chow and water were available ad libitum. All efforts were
made to minimize animal suffering and to reduce the number
of animals used in the study. Experimental protocols were
approved by the Institutional Animal Care and Use Committee
of our institution and were consistent with the guidelines
provided by the UK Animals (Scientific Procedures) Act 1986
and the guidelines of the Committee for Research and Ethical
Issues of IASP published in PAIN, 16 (1983): 109–10.
2.2. Preparation and administration of drugs
2.2.1. CCI-779
For intradermal (i.d.) administration, CCI-779 (temsirolimus;
Cat. No. T-8040; LC Laboratories, Woburn, MA, USA) at
a dose of 12.5 nmol (ie, 50 mL of 250 mM solution) was
prepared immediately before injections in a vehicle solution
containing 0.15 M NaCl, 5% polyethylene glycol 400, 5%
Tween 20, and 20% ethanol, similarly to our previous study.31
Intradermal injections were given over 1 minute in a volume of
50 mL in anaesthetized mice. Control animals received 50 mL
of equivalent vehicle solution without CCI-779. For systemic
(intraperitoneal [i.p.]) administration, CCI-779 was prepared in
pure ethanol as a stock solution at 60 mg/mL and diluted to
2.5 mg/mL in 0.15 M NaCl, 5% polyethylene glycol 400, 5%
Tween 20 immediately before injections, similarly to our
previous study.31 Mice were weighed and then injected i.p.
with a 1% vol/wt solution of CCI-779 (25 mg per kg body
weight) or an equivalent vehicle solution without CCI-779 as
a control group. CCI-779/vehicle was administered once 6
hours before injection of pruritogens. The concentration and
timing of CCI-779 injections were based on our previously
published report.31
2.2.2. Metformin
For systemic (i.p.) administration, metformin (metformin hydro-
chloride; Cat. No. 2864; Tocris Bioscience, Bristol, United
Kingdom) was prepared in sterile saline immediately before
injections. Mice were weighed and then injected i.p. with
metformin (200 mg per kg body weight) or equivalent vehicle
solution without metformin as a control group. Metformin/vehicle
was administered once 4 or 24 hours before injection of
pruritogens. The concentration and timing of metformin injections
were based on both previously published research using CCI-
779, rapamycin, or metformin18,26,31 and on our own pilot data in
rats suggesting that both CCI-779 and metformin were effective
in increasing thermal activation thresholds maximally in A-fibers 3
to 4 hours after systemic i.p. treatment. Indeed, mTORC1
signaling was inhibited by metformin in dissociated mouse
trigeminal neuron cultures within 1 hour.26
2.3. Induction of scratching behaviour
As previously published,42,43 itch was induced in B6 mice by
injection of pruritogens: histamine-dependent compound 48/80
(100 mg; Cat. No. C2313; Sigma-Aldrich, Suffolk, United
Kingdom) and histamine-independent chloroquine (chloroquine
diphosphate salt, 200 mg; Cat. No. C6628; Sigma-Aldrich) or
peptide SLIGRL-NH2 (100 mg; Cat. No. H-5078; Bachem,
Bubendorf, Switzerland; SLIGRL-NH2 was thought to be
a PAR-2 agonist, but it has been shown that SLIGRL-NH2
injection generates a histamine-independent itch through the
MrgprC11 receptor while a PAR2 ligand caused thermal
hypersensitivity22). Itch-inducing agents were dissolved in sterile
saline and immediately administered by i.d. injection into the nape
of the mouse neck in a volume of 50 mL. Before itch experiments,
the backof themouseneckwas shaved and animalswere given 30
minutes to acclimate to a small plastic chamber. For i.d. injections
of pruritogens, mice were removed from the chamber, gently
restrained, and i.d. injected. Itch behaviour in the mouse that
developed after i.d. injection of pruritogens was recorded with
a digital video camera and analysed. One scratch was defined as
a lifting of the hind limb toward the injection site (the shaved area of
the neck) and then replacing the limb back to the floor, regardless
of how many scratching strokes (bouts of scratching) took place
between those 2 movements.38 The scratching was quantified as
the total number of scratches across 40-minute observation period
plus the cumulative number of scratches observed for 40 minutes
at 5-minute intervals. In all experiments, the observer was not
aware of the substance and/or dose given. Eachmouse was used
only once, in 1 experiment.
2.4. Biochemical assays
2.4.1. Immunohistochemistry
To localize P-mTOR and GRP, naive mice were deeply anaes-
thetized with pentobarbital and perfused transcardially with saline
containing 5000 IU/mL heparin followed by 4% paraformaldehyde
in 0.1 M phosphate buffer containing 0.05 M sodium fluoride
(;100 mL per mouse). The glabrous skin of the hind paw around
the foot pads and the hairy skin from the back of the neck were
dissected out, postfixed in the same paraformaldehyde solution for
2 hours at 4˚C and transferred into a 30% sucrose solution in
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phosphate buffer containing 0.01% azide for a minimum of 24
hours. Tissue sections were cut at 40 mm on a freezingmicrotome
perpendicular to the surface of the skin.
Sections of the skin were blocked in PBS containing 0.2%
Triton X-100 and 5% normal goat serum for 1 hour at room
temperature. Sections were then left to incubate with rabbit
anti-phospho-mTOR (P-mTOR, Ser2448; 1:1000; Cat. No.
2971; Cell Signaling Technology Leiden, The Netherlands) for
3 days at 4˚C. A tyramide signaling amplification–based
protocol was used to amplify the P-mTOR signal.9,31
Appropriate biotinylated secondary antibodies were used at
a concentration of 1:400 for 90 minutes. Samples were then
incubated with avidin–biotin complex (ABC Elite; Vector
Laboratories, Peterborough, United Kingdom) (1:250 Vectas-
tain A1 1:250 Vectastain B) for 30 minutes followed by a signal
amplification step with biotinylated tyramide solution (1:75 for 7
minutes; Perkin Elmer Llantrisant, United Kingdom). Finally,
sections were incubated with FITC-avidin for 2 hours (1:600;
Vector Laboratories). The sections were then reprobed
with rabbit anti-GRP (1:100; Cat. No. 20073; Immunostar,
Newmarket, United Kingdom) for 24 hours at room tempera-
ture to determine cellular colocalization. The appropriate
directly labeled secondary antibody was applied at a concen-
tration of 1:500 and incubated for 2 hours. All sections were
coverslipped with Gel Mount Aqueous Mounting Medium
(Sigma-Aldrich) to protect the fluorescence from fading and
stored in dark boxes at 4˚C. Controls included omission of the
first or second primary antibodies. All images of double-stained
tissue were acquired by confocal microscopy using a laser
scanning microscope (Leica TCS NT SP) as described pre-
viously.9,31 Counts were taken from confocal images taken
using a 403 objective. Sections at least 240 mm apart taken
from each of the 3 mice were sampled, and a total of 30 to
50 GRP-positive fibers were analysed for P-mTOR-positive
immunoreactivity. Postacquisition processing was performed
with Adobe Photoshop and Adobe Illustrator.
2.4.2. Immunoblotting
CCI-779 inhibition of mTORC1 activity was shown previ-
ously.9,18,31 To verify the efficacy and specificity of mTORC1
inhibition by metformin in our experimental setting, we evaluated
activation of downstream components of the mTORC1 signaling
pathway in treated mice. Ribosomal protein S6K (S6 kinase) and
4EBP (eIF4E; eukaryotic initiation factor 4E–binding protein) are
well-characterized substrates for mTORC1. S6K activation
absolutely requires TORC1-mediated phosphorylation and
phosphorylates its own set of targets, many of which promote
protein production.24 In a parallel pathway, TORC1-mediated
phosphorylation of 4EBP1 initiates cap-dependent translation by
eIF4E.24 Therefore, we evaluated levels of phosphorylation of
mTOR (P-mTOR/mTOR), S6 ribosomal protein (P-S6/S6), and
4E-BP1/2 (P-4E-BP1/2/4E-BP1/2) as indicators of inhibition of
the mTORC1 pathway.
Mice were killed with CO2, decapitated, and the lumbar
(L4-L6) dorsal spinal cord and dorsal roots from naive animals
4 and 24 hours after i.p. injection of metformin and its
appropriate vehicle controls were quickly dissected out and
frozen on dry ice. Samples were then stored at 280˚C until
further processing. For protein extraction, samples were
homogenized by sonication in lysis buffer (1% Np-40,
20 mM Hepes pH 7.4, 100 mM NaCl, 100 mM NaF, 1 mM
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Figure 1. Intradermal (i.d.) administration of CCI-779 inhibited itch behaviour induced by histamine-dependent and histamine-independent pruritogens inmice. (A)
Time-course effect of i.d. injection of CCI-779 (12.5 nmol), or vehicle, on the total number of scratches that occurred over a 40-minute time period after i.d. injection
of compound 48/80, chloroquine, or SLIGRL-NH2 into the nape of the mouse neck. Mice received an i.d. injection of CCI-779 or vehicle 6 hours before the
injection of pruritic agents. Itch behaviour was recorded and scratches were counted in 5-minute intervals for 40minutes. (B) Bar graphs displaying a total number
of scratches across a 40-minute observation period for each treatment. Data are presented as mean 6 SEM values, n 5 5 to 6 in each group. The asterisk (*)
denotes significance vs vehicle control animals; *P, 0.05 (A, 2-way analysis of variance, followed by Bonferroni comparison post hoc test; B, unpaired student
t-test).
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Na3VO4, 5 mM EDTA with 13 protease inhibitor cocktail
[Sigma]; 13 phosphatase inhibitor cocktail I and II [Sigma-
Aldrich]) and incubated on ice for 2 hours. Samples were then
centrifuged at 12,000 rpm for 15 minutes and supernatants
were collected. Total protein concentration was assessed
using a bicinchoninic acid protein assay kit (Thermo Fisher
Scientific, Rockford, IL, USA) before each preparation of
protein samples. Tissue extracts (15-30mg of proteins per well)
were denatured and run on 12% Bis-Tris gels (Biorad, Hemel
Hempstead, United Kingdom). Proteins were electrophoreti-
cally transferred onto a PVDF membrane (Biorad Hemel
Hempstead, United Kingdom). After blocking nonspecific
binding site in 10 mM Tris-HCl pH 5 7.5, 150 mM NaCl,
0.05% Tween 20 (Sigma) with 0.24% I-Block (Applied
Biosystems, Paisley, United Kingdom) for 1 hour at room
temperature, membranes were incubated overnight at 4˚C with
primary antibodies as listed below. After three 10-minute washes,
an appropriate horseradish peroxidase (HRP)-conjugated
secondary antibody was applied for 1 hour at room temper-
ature. HRP activity was visualized by applying a chemilumines-
cent substrate (ECL; Amersham Pharmacia Biotech, Little
Chalfont, United Kingdom) or Pierce SuperSignal West Femto
(Thermo Fisher Scientific, Rockford, IL, USA) and using
ChemiDoc XRS (Biorad Hemel Hempstead, United Kingdom).
Membranes were then washed and incubated with GAPDH
antibody overnight at 4˚C and further processed as described
above. Primary antibodies were detected against phosphory-
lated rabbit mTOR (P-mTOR, Ser2448; 1:500; Cat. No. 2971),
rabbit S6 ribosomal protein (P-S6, Ser235/236; 1:200; Cat.
No. 2211), rabbit 4E-BP1/2 (P-4E-BP1/2, Thr37/46; 1:200;
Cat. No. 9495), and total rabbit mTOR (mTOR; 1:500; Cat. No.
2972), rabbit S6 (S6; 1:200; Cat. No. 2217), rabbit 4E-BP1/2
(4E-BP1/2; 1:200; Cat. No. 9452) (Cell Signaling Technology,
Leiden, The Netherlands), as well as against mouse GAPDH
(1:000; Millipore Bioscience Research Reagents, Watford, United
Kingdom) used as loading control.
Immunoreactive levels for all proteins were quantified by
integrating band density X area using computer-assisted
densitometry (Image J; NIH, MD). The density X area
measurements were normalized to that of its appropriate
GAPDH signal to provide a protein/GAPDH ratio and
expressed as a percent change from the mean value of
controls treated with vehicle for each individual protein. The
optical density of the phosphoprotein bands was divided by
that of the corresponding total protein band to yield
a phosphoprotein/total protein ratio. For each condition,
a minimum of 3 to 6 replicates from 3 to 6 different animals
were run. For an extra confirmation of equal loading of
proteins, membranes were stained with Ponceau dye and
staining of the wells visually compared.
2.5. Statistical data analysis
Data analysis and statistical comparisons were performed
using GraphPadPrism, version 6.00 for Windows (GraphPad
Software, CA, www.graphpad.com).
Behavioural and immunoblotting results are presented in
the graphs as mean 6 SEM. Each group included 5 to 6
animals in behavioural experiments or 3 to 6 animals in
immunoblotting approaches. Statistical analysis was per-
formed by 2-way analysis of variance with Bonferroni multiple
comparison post hoc tests for behavioural results and by
0 5 10 15 20 25 30 35 40
0
10
20
30
40
50
60
70
vehicle
CCI-779 (25 mg/kg i.p.)
Time after compound 48/80 [min]
N
um
be
r
of
sc
ra
tc
he
s
[c
ou
nt
s/
5
m
in
]
*
0 5 10 15 20 25 30 35 40
0
10
20
30
40
50
60
70
vehicle
CCI-779 (25 mg/kg i.p.)
*
Time after chloroquine [min]
0 5 10 15 20 25 30 35 40
0
10
20
30
40
50
60
70
vehicle
CCI-779 (25 mg/kg i.p.)
Time after SLIGRL-NH2 [min]
*
vehicle CCI-779 i.p.
0
100
200
300
400
*
Compound 48/80
To
ta
ln
um
be
r
of
sc
ra
tc
he
s
vehicle CCI-779 i.p.
0
100
200
300
400 Chloroquine
vehicle CCI-779 i.p.
0
100
200
300
400
*
SLIGRL-NH2
A
B
Figure 2. Intraperitoneal (i.p.) administration of CCI-779 inhibited itch behaviour induced by histamine-dependent and histamine-independent pruritogens inmice.
(A) Time-course effect of i.p. injection of CCI-779 (25 mg/kg), or vehicle, on the total number of scratches that occurred over a 40-minute time period after i.d.
injection of compound 48/80, chloroquine, or SLIGRL-NH2 into the nape of the mouse neck. Mice received an i.p. injection of CCI-779 or vehicle 6 hours before
the injection of pruritic agents. Itch behaviour was recorded and scratches were counted in 5-minute intervals for 40 minutes. B, Bar graphs are a total number of
scratches across a 40-minute observation period for each treatment. Data are presented as mean 6 SEM values, n5 6 in each group. The asterisk (*) denotes
significance vs vehicle control animals; *P , 0.05 (A, 2-way analysis of variance, followed by Bonferroni comparison post hoc test; B, unpaired student t-test).
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unpaired Student t-test for immunoblotting results. Behav-
ioural results are also represented as the total number of
scratches across 40-minute observation period, and statis-
tical analysis for these values was performed by unpaired
Student t test. A value of P, 0.05 was considered statistically
significant.
3. Results
3.1. Intradermal injection of CCI-779 reduces itch behaviour
in mice
We investigated whether the inhibition of mTORC1 signaling
pathway by i.d. injection of CCI-779 reduced the pruritic
response evoked by i.d. histamine-dependent (compound 48/80)
and histamine-independent (chloroquine, SLIGRL-NH2) pruri-
togens. Rapamycin and CCI-779 have been shown to inhibit
mTORC1 activity within the spinal cord, dorsal roots, and
cutaneous tissue and to inhibit mechanical hypersensitivity in
rodent models of neuropathic pain.18,31 As indicated in
Figure 1, i.d. injection of all 3 pruritogens induced scratching
behaviour that lasted for ;40 minutes. Statistically significant
inhibition of itch behaviour was observed for all 3 pruritogens
and for the whole observation period when compared
with vehicle control animals (Fig. 1A; compound 48/80:
F(1,77) 5 7.03, P 5 0.009; chloroquine: F(1,80) 5 9.14,
P 5 0.003; SLIGRL-NH2: F(1,72) 5 30.14, P , 0.0001). When
CCI-779 was injected i.d. 6 hours before subsequent pruritogen
treatment, the total number of scratches induced by i.d.
compound 48/80 and chloroquine (Fig. 1B) was significantly
decreased by approximately 26.16 4% (t(10) 5 2.01, P5 0.04)
and 33.9 6 6.9% (t(10) 5 1.91, P 5 0.04), respectively.
Additionally, in pilot studies, a 3-hour pretreatment period with
i.d. CCI-779 yielded comparable results for chloroquine and
compound 48/80 (data not shown). The strongest antipruritic
action for CCI-779 was observed in SLIGRL-NH2-elicited
scratching behaviour, with a reduction of 65.7 6 21.6%
(Fig. 1A; t(9) 5 4.69, P 5 0.0006).
3.2. Systemic injection of CCI-779 reduces itch behaviour
in mice
We also investigated whether systemic (i.p.) pretreatment with
CCI-779 produced an antipruritic effect. As before, the dose
of CCI-779 was as used previously29 and was shown to inhibit
mTORC1 activity and mechanical hypersensitivity in a mouse
model of neuropathic pain and inflammatory hyperalgesia.
CCI-779 was injected i.p. 6 hours before induction of
scratching behaviour by compound 48/80, chloroquine, or
SLIGRL-NH2 (Fig. 2). Pretreatment with CCI-779 significantly
reduced the total number of scratches throughout the whole
observation period for compound 48/80 and SLIGRL-NH2,
with a reduction of 61.7 6 29.6% and 44.3 6 10%,
respectively (compound 48/80: F(1,77) 5 39.19, P , 0.0001;
t(10) 5 3.66, P 5 0.004; SLIGRL-NH2: F(1,80) 5 32.15,
Figure 3. Phospho-mTOR (P-mTOR) immunoreactivity in the mouse skin was found within some gastrin-releasing peptide (GRP)–positive fibers. (A and B)
Confocal images of 40-mm thick frozen sections of footpad of the glabrous skin cut perpendicular to the plantar skin surface of the mouse hind paw. (C) Confocal
images of 40-mm thick frozen sections of hairy skin form the nape of the mouse neck cut perpendicular to the hairy skin surface. (A) Colocalization of P-mTOR
(green) and GRP (red) in fibers contained within a bundle of axons within the dermis of the foodpad. (B) Colocalization of P-mTOR (green) and GRP (red) in fibers
within the dermis of the foodpad. (C) Colocalization of P-mTOR (green) and GRP (red) in hairy skin. Arrows indicate double-labeled fibers. Arrowheads indicate
GRP-positive fibers not double labeled. In (A-C) the single staining for each antibody and the merged image are shown from left to right and double staining
appears in yellow. The dotted line in (B) indicates the border between the dermis and the epidermis of themouse skin. ep: epidermis, d: dermis. (A-C) merged from
12 to 51 z-focal planes (12-35 mm depth). Scale bars, (A-C) 5 25 mm.
August 2015·Volume 156·Number 8 www.painjournalonline.com 1523
  Copyright ! 2015 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.
P, 0.0001; t(10)5 3.36, P5 0.007) (Fig. 2A, B). In chloroquine-
elicited scratching behaviour, i.p. CCI-779 was only effective
in the first 20 minutes of the itch response, with a 28.7 6 5.7%
reduction of scratching in this period (chloroquine: F(1,37) 5
4.46, P 5 0.04; Fig. 2A).
3.3. P-mTOR is present in subsets of itch-sensitive fibers in
the mouse skin
Immunohistochemical staining of skin sections of naive adult
mouse hind paw showed that activated mTOR (phospho-
mTOR, P-mTOR) was expressed in some subsets of itch
sensitive afferents, identified from costaining with GRP,
a putative marker for some itch-specific fibers (Fig. 3).41,42
P-mTOR labeling within GRP-positive axons was generally
continuous and seen as either single fibers or more rarely within
small bundles of axons within the dermis (Fig. 3A). We were able
to trace single P-mTOR-double labeled axons for hundreds of
micrometers within the dermis (Fig. 3B). Counts of single
P-mTOR-positive fibers from the glabrous skin indicated that
,5% of GRP-positive fibers contained P-mTOR (n 5 3; 50-80
GRP fibers/animal monitored).
We also examined hairy skin sections from the base of the neck
of naive adult mice, as this was the area used in mice to evaluate
itch-related behaviour. Again, we found that P-mTOR was
expressed in subsets of GRP-positive fibers but in contrast to
the glabrous skin, and both P-mTOR and GRP positive fibers
were less abundant in number and could be traced only for ;10
to 15 mm (Fig. 3C). There was also a slight decrease in the
number of double-stained fibers present, with ,3% of GRP-
positive fibers contained P-mTOR (n 5 3; 30-50 GRP fibers per
animal monitored).
3.4. Systemic injection of metformin reduces itch behaviour
in mice
Metformin is a drug widely taken for type 2 diabetes and
recently shown to inhibit mTORC1 signaling and to reduce
mechanical hypersensitivity in a rodent model of neuropathic
pain.26 Here, systemic (i.p.) treatment with metformin injected
4 hours before pruritogens promoted a significant inhibition of
SLIGRL-NH2-elicited scratching behaviour with reduction in
scratching of 40.26 11.1% (F(1,176)5 21.64, P5 0, 0.0001;
t(22) 5 2.27, P 5 0.02; Fig. 4). Although the same metformin
treatment had a significant inhibitory effect in the chloroquine-
induced itch study with a reduction in scratching of 32.4 6
5.9% (F(1,72) 5 6.82, P 5 0.01), the total number of scratches
in 40-minute period did not show a significant difference (t(10)
5 1.34, P 5 0.11; Fig. 4). In addition, i.p. metformin 4 hours
before pruritogens did not significantly reduce scratching
behaviour caused by histamine-dependent compound 48/80
(Fig. 4). In contrast, when metformin was injected i.p. 24
hours before pruritogens, it significantly inhibited compound
48/80, chloroquine-, and SLIGRL-NH2-elicited scratching
behaviour, although the antipruritic effect for compound
48/80 was the weakest and observed only 10 to 20 minutes
after induction of itch (Fig. 5). The reduction of itch was as
follows: for compound 48/80 12.5 6 11.2% (F(1,24) 5 9.43,
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Figure 4. Intraperitoneal (i.p.) administration of metformin 4 hours prior to pruritogens inhibited itch behaviour induced by nonhistaminergic pruritic agents in
mice. (A) Time-course of i.p. metformin (200 mg/kg), or vehicle, in mice on the total number of scratches over a 40-minute period after i.d. injection into the
nape of the mouse neck of compound 48/80, chloroquine, or SLIGRL-NH2. Mice received an i.p. injection of metformin or vehicle 4 hours before the injection
of pruritic agents. Itch behaviour was recorded and scratches were counted in 5-minute intervals for 40 minutes. (B) Bar graphs displaying a total number of
scratches across 40-minute observation period for each treatment. Data are presented as mean6 SEM values, n5 6 in each group. The asterisk (*) denotes
significance vs vehicle control animals; *P , 0.05 (A, 2-way analysis of variance, followed by Bonferroni comparison post hoc test; B, unpaired student t-
test).
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P 5 0.005; t(8) 5 0.89, P 5 0.4), for chloroquine 51.6 6 5.2%
(F(1,72) 5 29.53, P , 0.0001; t(9) 5 3.63, P 5 0.003), and for
SLIGRL-NH2 44.9 6 13.4% (F(1,80) 5 13.62, P 5 0.0004; t(10)
5 2.38, P 5 0.009).
3.5. Systemic injection of metformin blocksmTORC1 activity
in dorsal roots
In vitro metformin has been shown to inhibit mTORC1 signaling
through activation of the AMPK pathway.6,26 We investigated
whether metformin, at the dose effective in reducing itch-related
behaviour, blocked the activity of mTORC1 in vivo in the spinal
cord and dorsal roots by quantifying the phosphorylation level of
direct downstream targets of mTORC1, S6 ribosomal protein,
and 4E-BP1/2. Dorsal roots were used as they are made up
almost exclusively of sensory fibers unlike the sciatic nerve that
contains large number of motor axons. As indicated in Fig. 6B,
systemic (i.p.) injection of metformin 4 hours before (at a dose
previously evaluated26) significantly reduced phosphorylation of
4E-BP1/2 in dorsal roots (t(5)5 3.9, P5 0.01) but not in the spinal
dorsal horn. When we analysed the activity of mTORC1 24 hours
after i.p. injection of metformin, we observed a significant
reduction of phosphorylation of mTORC1 and S6 ribosomal
protein in dorsal roots (t(10)5 1.92, P5 0.04 and t(14)5 2.13, P5
0.02, respectively; Fig. 7B) but no changes in the spinal dorsal
horn. However, a trend toward a reduction in 4E-BP1/2 did not
reach significance. Taken together, these data confirm that
mTORC1 activity was inhibited by i.p. metformin within sensory
fibers in the periphery rather than in dorsal horn.
4. Discussion
There is a pressing need for new treatments for both acute and
chronic pruritus, particularly those conditions that are insensitive
to antihistamines.3,16,27,40 Here, we show that the rapamycin
ester, CCI-779, attenuated both histaminergic and nonhistami-
nergic forms of itch, at a dose shown previously to inhibit the
mTORC1 activity in spinal cord and dorsal roots.18,31 Further-
more, we showed that metformin treatment also specifically
reduced nonhistamine-provoked itch and inhibited the mTORC1
(throughmeasurement of P-4E-BP1/2) activity in dorsal roots.We
therefore suggest that the reduction of the itch response seen
after either CCI-779 or metformin treatment was caused by
inhibition of mTORC1 within specific subsets of sensory primary
afferent fibers. Our previous research has established that
activated mTOR (P-mTOR) was mainly restricted to A-fibers,
whereas there was little evidence for extensive expression within
C-fibers.9,18,30,31,33 This correlated well with both electrophysi-
ologic and behavioural deficits reported after local, intrathecal, or
systemic (i.p.) treatment with the mTORC1 inhibitor rapamycin or
rapalogueCCI-779.18,31 However, themechanisms bywhich itch
is signaled to the CNS are currently under intense scrutiny and
considerable weight has been placed on signaling through
specific C-fiber primary afferents.12,17,25,29,37 Nevertheless, the
role of A-fibers in itch signaling is also established, if lacking in
molecular detail.11,34 Thus, our current observations emphasize
the role that A-fibersmay play in itch signaling and the importance
of the mTORC1 pathway in the regulation of some functions of
these primary afferents.
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Figure 5. Intraperitoneal (i.p.) administration ofmetformin 24 hours prior to pruritogens inhibited itch behaviour induced by histaminergic and nonhistaminergic pruritic
agents inmice. (A) Time-courseof i.p.metformin (200mg/kg), or vehicle, inmiceon the total number of scratchesover a 40-minute observationperiodafter i.d. injection
into the nape of themouse neck of compound48/80, chloroquine, or SLIGRL-NH2.Mice received an i.p. injection ofmetformin or vehicle 24 hours before the injection
of pruritic agents. Itch behaviour was recorded and scratcheswere counted in 5-minute intervals for 40minutes. (B) Bar graphs displaying a total number of scratches
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4.1. Itch-specific primary afferent fibers
Evidence has been presented to show that GRP-containing
primary afferent neurons and those expressing one of the Mas-
related G protein-coupled receptor family members MrgprA3
were essential for the full expression of scratching after dermal
injections of both the histamine-releasing compound 48/80 and
the nonhistaminergic agents, chloroquine and SLIGRL-NH2 in
mice.5,22,12 MrgprA3-expressing dorsal root ganglion (DRG) cells
represent a very small population of largely C-fibers that project to
the superficial dorsal horn where the majority synapse onto
interneurons expressing the GRP receptor (GRPR).12 In addition,
recent research has suggested that the GRP-GRPR pathway is
primarily engaged in transducing nonhistaminergic acute itch
sensation and may play a relatively minor role in histaminergic
itch.46 Peripheral activation of dorsal horn neurons that express
GRPR was also shown to be mediated through C-fibers and to
involve glutamate release, although some Ad fiber signaling was
also reported.20 However, the location of GRP-immunoreactive
neurons in neural circuits mediating itch remains controver-
sial.39,43,45 Although Zhao et al.45 reported resting levels of GRP
in a small number of DRG neurons (;7%) confirming the original
report of Sun et al.,43 recent reports failed to find GRP in DRG cell
bodies unless the peripheral nerve had been sectioned 3 days
previously.39 Here, we were able to detect for the first time a small
number of GRP/P-mTOR colabelled primary afferent fibers in the
mouse dermis. Given the controversy around the presence of
GRP in DRGs, it may be that some GRP is locally transcribed
under the control of mTORC1 only in the terminal processes of
a subpopulation of these GRP/P-mTOR-positive cutaneous
afferents. If this was the case, it might also be suggested that in
diseases with comorbid pruritus,16 circulating factors associated
with the disease state may enhance the translation of peripheral
GRP through activation of mTOR and thus facilitate itch. It should
also be noted that the presence of GRPR was detected in the
dermis of healthy human adults.41 Thus, together with our
previous work on the characterization of P-mTOR-positive fibers,
we would suggest that the small number of GRP and P-mTOR-
positive fibers may well be the itch Ad fibers previously
identified.30 Therefore, inhibition of mTORC1 activity in these
fibers potentially may contribute to the reduced itching seen after
CCI-779 or metformin treatment.
4.2. Itch and A-fibers
Although labeled line theories of itch signaling have gained
ground, a parallel series of investigations has uncovered complex
interactions between primary afferents that were not predictable
purely on the basis of a dedicated itch signaling pathway.35,28 For
example, deletion of the vesicular glutamate transporter gene
from primary afferents or ablation of a subset of inhibitory
interneurons within the dorsal horn produces spontaneous
itching and increased sensitivity to all types of pruritic stimuli.
These results strongly imply that interactions between incoming
primary afferents within the dorsal horn are necessary for the
B
A
Figure 6. Intraperitoneal (i.p.) administration of metformin 4 hours prior to pruritogens decreased phosphorylation of the downstream target of mTORC1, 4E-BP1/
2 in dorsal roots. (A and B) Effects of i.p. injection of metformin (M; 200mg/kg), or vehicle (V), on the level phospho-mTOR (P-mTOR) and total mTOR, phospho-S6
ribosomal protein (P-S6), and total S6 protein, as well as phospho-4E-BP1/2 (P-4E-BP1/2) and total 4E-BP1/2 in the dorsal spinal cord (A) and dorsal roots (B).
Mice received an i.p. injection of metformin or vehicle 4 hours before sacrifice. The intensity of the bands for each antibody was normalized with the intensity of its
appropriate GAPDH signal. Each graph represents the phosphoprotein/total protein ratio, mean 6 SEM values, n 5 3 to 6 per each experimental group. The
asterisk (*) denotes significance vs vehicle controls; *P, 0.05 (unpaired Student t test). Representative immunoblots are shown above the appropriate graph bar.
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experience of acute and chronic itch.21,23,36 Also, in addition to
the well-known antagonistic interaction between pain and itch,
similar patterns of peripheral and central sensitization have also
been characterized. Noxious input to the spinal cord is known to
provoke central sensitization reported behaviourally as allodynia
and punctate mechanical hyperalgesia.4,11,14,16 Punctate me-
chanical hyperalgesia results in slightly painful pinprick stimula-
tion being perceived as more painful in the secondary zone
around a focus of inflammation or injury. Injury sets up central
sensitization primarily through activation of C-fiber nociceptors,
and this has been shown to amplify inputs from subsets of
A-fibers recorded behaviourally as punctate mechanical hyper-
algesia. These A-fibers also contain activated mTOR and local
subcutaneous, intrathecal, or systemic treatment with mTORC1
inhibitors attenuated both experimentally induced punctate
hyperalgesia and predictably neuropathic mechanical sensitivity
in rodents.9,18,31 A strikingly similar pattern of central sensitization
is observed in the itch pathway: local injection of a pruritic agent
produces touch- or brush-evoked pruritus around the itching
site.3 Hyperkinesis, itch becoming more intense in the area
around pruritic stimulation, has been reported after histamine
iontophoresis and provides compelling evidence for the existence
of central sensitization for itch.2,4,27,36 It has also been shown that
small myelinated fibers can contribute to both nonhistaminergic
and histaminergic itch28,34 implying that there are parallel
pathways signaling itch to the dorsal horn. Thus, itch-specific
C-fibers trigger central sensitization, which amplifies itch-related
signals transmitted by A-fibers. Therefore, we suggest that
inhibition of mTORC1 signaling pathways by CCI-779 may
reduce activity in itch-sensitive A-fibers leaving C-fiber signaling
intact. Indeed, it was found that itch sensation produced by
cowhage (similarly to SLIGRL-NH2-induced itch stimulation that
is now confirmed to act at MrgprC1122) was reduced during
A-fiber block, and recent studies confirmed the contribution of
A-fiber signaling to cowhage-induced itch and to histamine-
mediated itch sensation.11,28,34
4.3. Metformin as an antipruritic agent
We showed that systemic (i.p.) treatment with the biguanide drug
metformin, widely given to treat type 2 diabetes, attenuated
specifically scratching to nonhistaminergic (chloroquine and
SLIGRL-NH2) but less effectively histaminergic (compound 48/
80) pruritic stimuli. We also showed that systemic treatment with
metformin inhibited mTORC1-substrate eukaryotic initiation
factor 4E–binding protein (4E-BP/2) and S6 ribosomal protein
within the dorsal roots but not spinal cord. This was consistent
with the observation that metformin and rapamycin or its analogs
have been reported to have similar effects on mechanical
hyperalgesia in neuropathic pain models.26 As mentioned above,
mTOR exists in 2 complexes: mTORC1, which is sensitive to the
drug rapamycin, and mTORC2, which is not. The 2 best
established substrates of mTORC1, p70-S6 kinase and 4E-
BP1/2, control unique aspects of mRNA translation,24 and
A
B
Figure 7. Intraperitoneal (i.p.) administration of metformin 24 hours prior to pruritogens decreased phosphorylation of mTORC1 and its downstream target, S6
ribosomal protein in dorsal roots. (A and B) Effects of i.p. injection of metformin (M; 200 mg/kg), or vehicle (V), on the level phospho-mTOR (P-mTOR) and total
mTOR, phospho-S6 ribosomal protein (P-S6), and total S6 protein, as well as phospho-4E-BP1/2 (P-4E-BP1/2) and total 4E-BP1/2 in the dorsal spinal cord (A)
and dorsal roots (B). Mice received an i.p. injection of metformin or vehicle 24 hours before sacrifice. The intensity of the bands for each antibody was normalized
with the intensity of its appropriate GAPDH signal. Each graph represents the phosphoprotein/total protein ratio, mean 6 SEM values, n 5 3 to 6 per each
experimental group. The asterisk (*) denotes significance vs vehicle controls; *P, 0.05 (unpaired Student t-test). Representative immunoblots are shown above
the appropriate graph bar.
August 2015·Volume 156·Number 8 www.painjournalonline.com 1527
  Copyright ! 2015 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.
blocking mTORC1-regulated translation in A-fiber axons is
thought to result in a decrease in primary afferent excitability.18,30
Rapamycin or rapalogues such as CCI-779 are allosteric
inhibitors of mTORC1 through their binding to the immunophilin
protein FKBP12 that binds specifically to mTORC1. The
mechanisms behind the inhibition of protein translation by
metformin are less well understood6,8 but involve upstream
pathways of mTORC1 including activation of AMPK, as well as
the AMPK effectors, LKB1, and tuberous sclerosis complex 2.6,8
The failure of metformin to inhibit histamine-sensitive itch was
unexpected but may be accounted for by the fact that inhibition
bymetformin of mTORC1 (through 4E-BP1/2) activity is restricted
to dorsal roots and not spinal cord (at this time point), whereas
CCI-779 inhibition extends to the spinal cord.31 It is also likely that
itch is signaled through overlapping subsets of primary afferent
fibers,1 which are in some cases insensitive to metformin
inhibition. For example, it was recently reported that GRP
antagonists would inhibit nonhistaminergic itch, but not that
elicited by histamine, and that histamine responses at the H1
receptor on C-fibers were unique in requiring phospholipase Cb
as an intracellular mediator.1,13,42
In conclusion, the data presented here provide, for the first
time, evidence that the mTORC1 signaling pathway regulates
both histamine-dependent and histamine-independent itch.
Together with our previous studies on the role of mTORC1 in
pain,9,18,30,31 this result may suggest that a subpopulation of
P-mTOR-positive A-fibers may also be crucial for the full
response to pruritic stimuli and therefore may underline the
importance of the mTORC1 pathway in the regulation of
homeostatic primary afferent functions such as pain and itch.
Moreover, here we revealed a novel pharmacological action for
metformin that may be therapeutically useful for the treatment of
patients suffering from chronic pruritus not responsive to
antihistamines.
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